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Abstract

Background: The Food and Drug Administration (FDA) issued a safety alert in 2017 regarding
increased risk of cardiovascular death with febuxostat compared to allopurinol. The drug label of
febuxostat already carried a warning sign for cardiovascular adverse events since it was approved in
2009. An additional post-marketing safety trial showed that for all the combined cardiovascular
outcomes, febuxostat did not increase the risk compared to allopurinol but it showed an increased risk
of cardiovascular mortality. On February 21st, 2019, FDA added a black boxed warning for increased
risk of death with febuxostat compared to allopurinol.
Objective: To compare the incidence of cardiovascular events of febuxostat and allopurinol in patients
with gout/hyperuricemia and to investigate comparative efficacy of febuxostat and allopurinol on
lowering the uric acid levels
Methodology: A hospital-based retrospective cohort study was conducted for a one-year period in
hyperuricemia/gout patients admitted from 2013 to 2017. Study cohort (febuxostat/allopurinol/both)
and control cohort (drugs other than febuxostat/allopurinol) were selected based on inclusion and
exclusion criteria. These patients were retrospectively followed until 31st December 2018. The primary
outcomes were cardiovascular events such as cardiovascular death, non-fatal stroke, non-fatal
myocardial infarction, urgent revascularization of unstable angina, hospitalization due to heart failure,
venous thromboembolism, arrhythmia, transient ischemic attack, urgent cerebrovascular
revascularization, death from any cause. IBM SPSS version 20 was used to perform statistical analysis
and p<0.05 was considered as statistically significant for all the analysis.
Results: The mean difference in the serum urate level for febuxostat was 2.754 mg/dl [p=0.000; CI
(95%) 2.209-3.299] and for allopurinol was 1.137 mg/dl [p=0.000; CI (95%) 0.792-1.482]. This
indicated both the drugs have the ability in reducing the serum urate levels. However, no significant
difference was found between them. The mean survival time for febuxostat was found to be 37 months
[CI (95%) 24-51], for allopurinol 107 months [CI (95%) 52-162] and for the group with both drugs it
was 38 months [CI (95%) 20-56]. The mean survival time was lesser in febuxostat group than in
allopurinol group. However, there was no significant difference between the two groups (p=0.762).
Cardiovascular events occurred in 4 out of 71 patients (5.63%) in febuxostat group, 6 out of 93 patients
(6.45%) in allopurinol group and 3 out of 10 patients (30%) in group with both drugs. The number
needed to harm (NNH) for febuxostat, allopurinol and combination were 22, 19 and 3 respectively in
our study. This indicates that there is one cardiovascular event for every 22 patients who are exposed
to febuxostat, 19 patients who are exposed to allopurinol and 3 patients who are exposed to both.
Conclusion: Our study shows that both febuxostat and allopurinol are significantly efficacious in
reducing serum urate levels. The mean survival time was less for febuxostat compared to allopurinol,
which means that cardiovascular events occurred faster in febuxostat group. Incidence of
cardiovascular events was more in allopurinol group than in febuxostat group. However, there was no
significant difference in these results due to less sample size. Similar to the FDA report, our study also
reported that cardiovascular events might occur with chronic usage of febuxostat, allopurinol or both.
Therefore, these drugs must be prescribed with caution and should be monitored in patients who
already have risk factors for developing cardiovascular diseases.

2|Page

INTRODUCTION

3|Page

Introduction

Hyperuricemia is a condition where the uric acid level in the blood is high

[1]

. The normal uric acid

level in our blood is 2.4-6.0 mg/dl for female and 3.4-7.0 mg/dl for male [2]. The body normalizes uric
acid levels by keeping a balance between purine input (through diet), amount of uric acid generated
(via turn-over of a cell) and the amount which is eliminated in urine or through GIT

[3]

. At the same

time, gout is a type of inflammatory arthritis where there are repeated attacks of a tender, hot, red
and swollen joint

[4]

. The main reason for gout is persistent high levels of uric acid. Crystals of uric

acid deposit itself in joints, tendons and other near-by tissues which causes a “Gout attack” [5].
The general occurrence of gout among the population is 1 - 4%. It occurs in 3 - 6% of men and 1 -2%
of women. Annual incidence is 2.68 per 1000 persons. Men are 2-6 times more prone than women.
Globally the cases of gout are on the rise due to poor diet habits like fast foods and lack of physical
activity [6].
Hyperuricemia happens due to lack of elimination or high synthesis of uric acid, or, a combination of
the two. Under-producers consist of the majority of cases and over producers form the minority group.
Under producers have altered uric acid elimination which is due to low glomerular filtration, tubular
secretion, or high tubular reabsorption. The reason for over producers is either exogenous (high purine
diet) or endogenous (high purine nucleotide breakdown). A minor proportion of patients can have
enzymatic defects like deficiency of hypoxanthine-guanine phosphoribosyltransferase (HGPRT)
enzyme. The most common reason for combined mechanism is alcohol consumption, which leads to
the breakdown of adenosine triphosphate (ATP) which generates organic acids which compete with
urate for tubular secretion. Other causes are enzymatic defects such as glycogenoses type I and
aldolase- B deficiency [7].
Allopurinol is very commonly used in the treatment of hyperuricemia [8]. Recommended normal dose
is 200-300 mg/day. Allopurinol is ideally used in uric acid overproducers, patients with renal
impairment, nephrolithiasis, or tophaceous gout and patients at risk for developing nephropathy due to
high uric acid

[7]

. According to FACT trial, febuxostat (80/120 mg per day) was much better than

allopurinol (300 mg/day) in lowering serum urate levels. Hence, febuxostat was approved by USFDA
in 2009

[9]

. The recommended dose is 40 mg orally once daily which can be titrated to 80 mg once

daily if the desired serum uric acid levels (6 mg/dl) is not reached within two weeks [8].
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Need for the study
Both allopurinol and febuxostat are very commonly used for the treatment for hyperuricemia. In
patients who have mild to moderate impaired renal function, febuxostat was better than allopurinol (at
all doses) in lowering uric acid levels. Overall, febuxostat was equally safe as allopurinol in the
CONFIRMS trial

[10]

. However, other studies (CARES trial) have identified cardiovascular events

with febuxostat, and various on-going clinical trials (FAST trial) are comparing the cardiovascular
safety of febuxostat versus allopurinol. In gout patients with major cardiovascular comorbidities,
febuxostat equally caused adverse cardiovascular events compared to allopurinol. However, the
number of cardiovascular deaths were higher with febuxostat than with allopurinol [11].

FDA has put out a statement that there is an increased risk of death with febuxostat compared to
allopurinol based on a safety clinical trial that found a high-risk of heart-related death and death from
all causes with febuxostat. FDA posted the latest update advising general practitioners to prescribe
febuxostat only in refractory patients or who cannot tolerate allopurinol

[12]

. The studies so far done

with febuxostat and allopurinol to compare safety and efficacy are in the western population.
Extrapolating these data to other population such as South-Asians may not be pragmatic. There are
no such studies performed in Indian population with febuxostat and allopurinol. Therefore, this study
was designed to compare the cardiovascular safety profile of febuxostat and allopurinol in our settings.
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Objectives
•

To compare the incidence of cardiovascular events with the use of febuxostat and allopurinol
in patients with gout/hyperuricemia

•

To compare the efficacy of febuxostat and allopurinol on lowering the uric acid levels
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Methodology
•

Study site: Kasturba Hospital, Manipal

•

Study Design: Retrospective cohort study

•

Study Duration: 1 year

•

Sample size: The retrospective cohort consists of 270 patients, out of which 174 are study
cohort and 96 are control cohort. Out of 174 study cohort, 71 patients received febuxostat, 93
patients received allopurinol and 10 patients received both the drugs.

•

Ethical clearance: Ethical clearance was obtained from Institutional Ethics Committee,
Kasturba Hospital, Manipal (IEC: 479/2018) on 15th August 2018.

•

Study criteria:

➢ Inclusion Criteria:
❖ Patients diagnosed with gout or hyperuricemia.
❖ Patients who received either Febuxostat or Allopurinol for the treatment of gout.
❖ Both genders
❖ Patients above 18 years
➢ Exclusion Criteria:
❖ Incomplete case records
❖ Patients with a prior history of cardiovascular diseases.
❖ Patients prescribed with other drugs of potential cardiovascular adverse effects
•

Materials and Methods:

1. Data Collection
In-patient medical records were collected based on the inclusion and exclusion criteria from
the Medical Records Department (MRD) of Kasturba Hospital (KH), Manipal. Supplement
data were obtained from an online database from KH management system (Lab Report
Viewer). All the patients who received either febuxostat or allopurinol during the year 20132017 were selected as study cohort. For control cohort, patients who did not receive either
febuxostat and allopurinol during 2013-2017 were selected from orthopedics and medicine
department. These patients were retrospectively followed until 31st December 2018. The
primary outcomes were cardiovascular events such as cardiovascular death, non-fatal stroke,
10 | P a g e

non-fatal myocardial infarction, urgent revascularization of unstable angina, hospitalization
due to heart failure, venous thromboembolism, arrhythmia, transient ischemic attack, urgent
cerebrovascular revascularization, death from any cause. These patient records were reviewed
and the details were entered in a Case Report Form (Appendix 2 ).

2. Study materials used
Case report forms (CRF)
A suitable CRF was designed to collect the patient’s data from the medical record. Various
parameters like demographical details, medical history, risk factors, gout/hyperuricemia
treatment parameters (drug onset, dose, frequency, usage pattern), disease outcome and follow
up data were collected.

3. Statistical methods
Data analysis was performed using Statistical Package for Social Sciences (SPSS) Statistics
version 20.0. Survival analysis was performed to compare the mean survival time between
allopurinol and febuxostat group with cardiovascular outcomes. Paired T-test was done to
compare the efficacy of each treatment within the group. Repeated measures ANOVA was
performed to compare efficacy between the two groups.

4. Subject recruitment method
a. Study cohort enrolment:
Patients with gout/hyperuricemia during the year 2013-2017 were identified from the Medical
Records with the help of International Classification of Diseases (ICD) coding-10. Then, the
patient records were reviewed and the patients who received either febuxostat or allopurinol
were selected as study cohort. The required information was collected from the patient files in
the MRD and entered in the CRFs.
b. Control cohort enrolment:
Patients who did not receive either febuxostat or allopurinol or both during 2013-2017 were
randomly selected from orthopedics and medicine department of the Kasturba Hospital,
Manipal. The required information was collected from the patient files in the MRD and entered
in the CRFs.
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5. Outcome
The primary outcome measures are the occurrence of cardiovascular death, non-fatal stroke,
non-fatal myocardial infarction, urgent revascularization of unstable angina, hospitalization
due to heart failure, venous thromboembolism, arrhythmia, transient ischemic attack, urgent
cerebrovascular revascularization, death from any cause.
6. Study flow chart
Figure 1: Study flow chart

Screening of Hospital Inpatient
database

Control Cohort

Study Cohort

(Patients without Febuxostat,
Allopurinol or both)

(Patients with Gout/Hyperuricemia
receiving Febuxostat, Allopurinol or
both)

Febuxostat

CV
outcome

No CV
outcome

Allopurinol

CV
outcome

CV
outcome

No CV
outcome

No CV
outcome
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RESULTS
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Results

1. Patient demographics overview
A total of 270 hyperuricemia/gout patients were taken for the study from 1st January 2013 –
31st December 2017. Of these, 174 hyperuricemia/gout patients were study cohort who
received either febuxostat or allopurinol or both the drugs and 96 were control cohort who were
randomly selected and did not receive either of the two drugs.

Table 1: Patient demographic characteristics
Parameters

Study Cohort (N=174)

Control Cohort (N=96)

Mean age (in years)

51

48

Male

159 (91.4%)

62 (64.6%)

Female

15 (8.6%)

34 (35.4%)

Gender

Drug given
Allopurinol

93 (53.4%)

Febuxostat

71 (40.8%)

Both

10 (5.7%)

----

Cardiovascular events
Yes

13 (7.5%)

1 (1%)

No

161 (92.5%)

95 (99%)

In study cohort, 159 (91.4%) patients were male and 15 (8.6%) patients were female. In control
cohort, 62 (64.6%) were male and 34 (35.4%) were female. Majority of the hyperuricemia/gout
patients (53.4 %) received allopurinol, followed by febuxostat (40.8%). On the other hand,
5.7% study cohort patients received both febuxostat and allopurinol.
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2. Incidence of cardiovascular events
Figure 2: Incidence of cardiovascular events in study cohort

7.5%

Cardiovascular outcomes
No Outcome

92.5%

In study cohort, 13 (7.5%) patients developed cardiovascular events and 161 (92.5%) patients did
not develop any cardiovascular events. In control cohort, out of 96 patients, only 1 (1.04%) patient
developed cardiovascular event.
3. Incidence of cardiovascular events for each drug
Figure 3: Incidence of cardiovascular events for each drug

Both

Febuxostat

Allopurinol

0

1

2

3

4

5

6

7

Out of the 13 patients in the study cohort who had developed cardiovascular events, six patients
had received allopurinol, four patients had received febuxostat and three patients had received
both allopurinol and febuxostat.
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4. Incidence of different cardiovascular events in the study cohort
Figure 4: Incidence of different cardiovascular events in the study cohort

4.5
4
3.5
3
2.5
2
1.5
1
0.5
0

CVD: Cardiovascular disease; NFS: Non-fatal stroke; RV: Urgent revascularization due to unstable angina; ART: Arrhythmia; NF MI: Nonfatal myocardial infarction; HSP HF: Hospitalization for heart failure; VTE: Venous thromboembolism; IHD: Ischemic heart disease

5. Incidence of cardiovascular events based on the drugs

Figure 5: Incidence of cardiovascular events based on the drugs
3.5
3
2.5
2
1.5
1
0.5
0

Febuxostat
Allopurinol
Both drugs
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6. Dose Vs Cardiovascular events

Table 2: Dose of febuxostat Vs cardiovascular events

Cardiovascular
event

Dose of febuxostat
40 mg

80 mg

120 mg

Yes

5

0

0

No

59

9

1

Total

64

9

1

In patients who received febuxostat, 3 dose patterns were observed : 40 mg/day, 80 mg/day and 120
mg/day. All the patients who had developed cardiovascular events in the febuxostat group had received
40 mg/day.

Table 3: Dose of allopurinol Vs cardiovascular events

Cardiovascular
event

Dose of allopurinol
100 mg

200 mg

300 mg

400 mg

Yes

1

4

2

0

No

15

45

30

1

Total

16

49

32

1

In patients who received allopurinol, 4 dose patterns were observed: 100 mg/day, 200 mg/day, 300
mg/day, 400 mg/day. Among patients who developed cardiovascular outcome, 1 patient had received
100 mg/day dose, 4 patients received 200 mg/day and 2 patients received 300 mg/day.
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7. Number needed to harm (NNH)

Table 4: Number needed to harm for cohort study
Study population
Study Cohort

Cardiovascular
events
13

No cardiovascular
events
161

Total
174

Control Cohort

1

95

96

Total

14

256

270

NNH = 1/ Incidence in exposed- Incidence in non-exposed
= 15.625 ~ 16
This indicate that every 16 patients who received febuxostat / allopurinol or combination, one patient
developed cardiovascular events.
Table 5: Number needed to harm for Febuxostat
Study population

No cardiovascular
events
67

Total

Febuxostat group

Cardiovascular
events
4

Control group

1

95

96

Total

5

162

167

71

NNH = 21.73 ~ 22
This indicate that every 22 patients who received febuxostat, one patient developed cardiovascular
events.
Table 6: Number needed to harm for Allopurinol
Study population

No cardiovascular
events
87

Total

Allopurinol group

Cardiovascular
events
6

Control group

1

95

96

Total

7

182

189

93

NNH = 18.51 ~ 19
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This indicate that every 19 patients who received febuxostat, one patient developed cardiovascular
events.
Table 7: Number needed to harm for patients who received both drugs
Study population
Both

Cardiovascular
events
3

No
cardiovascular Total
events
7
10

Control group

1

95

96

Total

4

102

106

NNH = 3
This indicate that every 3 patients who received both the drugs, one patient developed cardiovascular
events.
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8. Survival analysis

Table 8: Comparative survival analysis of the drugs
Drug given

Mean (in
months)

95% CI
Lower

Upper

Febuxostat

37

24

51

Allopurinol

107

52

162

Both

38

20

56

p value*

0.762

CI: Confidence Interval; p: Probability; * Kaplan meier analysis

The mean survival time for febuxostat was found to be lesser (37 months) than allopurinol (107
months) and both the drugs (38 months).

Figure 6: Comparative survival analysis of the drugs
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9. Comparative efficacy of febuxostat and allopurinol

Table 9: Change in serum urate levels in febuxostat group and allopurinol
Drugs

Measures

Initial serum urate level (mg/dl)

Final serum urate level
(mg/dl)

Febuxostat

Mean

8.992

6.237

SD

2.211

2.062

Mean

7.984

6.847

SD

1.903

1.732

Allopurinol

SD: Standard Deviation

Table 10: Comparative efficacy of febuxostat and allopurinol in reduction of serum urate level
Drugs

Mean
Difference

95% CI
Lower

Upper

p value*

Percentage reduction

Febuxostat

2.754

2.209

3.299

0.000

30.6%

Allopurinol

1.137

0.792

1.482

0.000

14.2%

CI: Confidence Interval; p: Probability *Paired T test

The mean difference of the initial and final serum urate level for febuxostat and allopurinol is 2.754
mg/dl [p=0.000; CI(95%) 2.209-3.229] and 1.137 mg/dl [p=0.000; CI(95%) 0.792-1.482] respectively.
Both the drugs showed a significant reduction in serum uric acid levels. The percentage reduction for
febuxostat was 30.6% and allopurinol was 14.2%.

Table 11: Comparative efficacy in between the drug groups using repeated measures ANOVA
Source

f value

p value*

Group

0.632

0.428

f: ratio of between-groups to within-groups variances ; p: Probability; *Repeated measures ANOVA

There was no significant difference between allopurinol and febuxostat group in lowering the serum
urate levels.
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Figure 7: Comparative reduction of serum urate levels in Febuxostat & Allopurinol (Pre and
Post

1-Pre
Post

2-Post
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Discussion

In our study, cardiovascular events were seen in 13 patients out of 174 cases. 4 out of 71 patients were
in (5.63%) in febuxostat group, 6 out of 93 patients (6.45%) in allopurinol group and 3 out of 10
patients (30%) in the group receiving both drugs. Whereas in CARES trial, the primary end-point event
(same as the cardiovascular events included in our study) occurred in 335 patients (10.8%) in
febuxostat group and in 321 patients (10.4%) in the allopurinol group [11]. In our study, there was one
cardiovascular death in allopurinol group. Whereas in CARES trial, cardiovascular deaths were higher
in the febuxostat group than in the allopurinol group [11]. However, we cannot conclude on this as the
sample size was not equal in between the groups (71 for febuxostat group and 93 for allopurinol group).

There were no previous studies done for estimating the mean survival time of febuxostat and
allopurinol and number needed to harm (NNH). Therefore, we have included these two parameters in
our objective. In our study, we found the mean survival time for febuxostat to be 37 months [CI (95%)
24-51], which is lesser than both the allopurinol group i.e. 107 months [CI (95%) 52-162] and the
group receiving both drugs i.e. 38 months [CI (95%) 20-56]. However, there was no significant
difference found between the two (p=0.762). This might be due to less sample size in our study. We
also found the number needed to harm for febuxostat to be 19, 22 for allopurinol and 3 for group
receiving both the drugs.

In our study, the mean difference of the initial and final serum urate level for febuxostat was 2.754
mg/dl [p=0.000; CI (95%) 2.209-3.299] and for allopurinol it was 1.137 mg/dl [p=0.000; CI (95%)
0.792-1.482]. Both of the drugs were efficacious in reducing serum urate levels. However, we did not
observe a significant difference between the drugs in reducing serum urate levels. Similarly,
CONFIRMS trial concluded equal efficacy for both febuxostat (40 mg) daily and allopurinol (300/200
mg) daily in lowering serum urate levels. But they found at all level of renal function, febuxostat (80
mg) was more efficacious to both febuxostat (40mg) and allopurinol (300/200 mg) and was
comparatively safer to use. Whereas in mild or moderate renal impairment, febuxostat 40 mg daily
was significantly much better in lowering serum urate than allopurinol

[10]

. On the other hand, the

FACT trial reported that febuxostat (80/120 mg per day) was much better than allopurinol (300 mg
per day) in lowering serum urate levels [13].
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Conclusion
✓ Our study shows that both febuxostat and allopurinol are significantly efficacious in reducing
serum urate levels, but we could not compare efficacy between the two groups probably due to
low sample size.
✓ Our study shows that both febuxostat and allopurinol cause increased risk of cardiovascular
events with chronic use. Incidence of cardiovascular events was more in allopurinol group than
in febuxostat group.
✓ The mean survival time is lesser in febuxostat than allopurinol.
✓ Due to low sample size and a minimal number of outcome events we could not conclude on
other confounding factors involved.
✓ Therefore, these drugs must be prescribed with caution and should be monitored in patients
who already have risk factors for developing cardiovascular diseases. Patients should inform
the doctors if they already have some cardiovascular ailments/history of some kind and report
any kind of symptoms experienced after the use of these drugs immediately.
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Limitations of the study

The following are the limitations:
o The current study is done on a small sample size in a single center. Therefore, the result of the
study cannot be generalized throughout the population.
o Since the study is a retrospective design, there is a limitation for data availability and high
volume of missing data. Hence the accuracy of the data is uncertain.
o Patients with cardiovascular risk factors were also included in study cohort, but the hazard ratio
for the risk factors related to the end point could not be calculated due to less number of
outcome.
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Future directions
•
•

A multicentric randomized controlled study should be performed to determine comparative
safety and efficacy of allopurinol and febuxostat.
Impact of different doses of allopurinol and febuxostat on clinical and biochemical
improvement in hyperuricemia/gout patients.
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